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Abstract
Purpose: Sexual dysfunction is a common but often overlooked secondary symptom of multiple
sclerosis (MS) and can be associated with a decreased health-related quality of life (HRQoL).
Natalizumab is a disease-modifying therapy approved for the treatment of relapsing forms of MS.
In addition to its efficacy, those using natalizumab have shown improvement in HRQoL parameters,
including fatigue and cognition. The idea that improvement in fatigue may also correlate with improvement in sexual dysfunction is the impetus for this study.
Methods: A single-center, open-label, single-arm, 24-week study was performed to evaluate perceived
change in sexual dysfunction in MS patients treated with natalizumab. Adults with relapsing MS initiating natalizumab treatment and had a baseline level of sexual dysfunction were enrolled. The primary
endpoint was change in the MS Intimacy and Sexuality Questionnaire-19 (MSISQ-19) score from
baseline to week 24. Mean age of patients was 41 years, median disease duration was 7 years, and
73% of patients used at least one prior MS disease-modifying therapy.
Results: Natalizumab-treated patients experienced improvement in sexual dysfunction within the first
24 weeks of starting therapy, as demonstrated by the primary subscale of the MSISQ-19 questionnaire
(–0.6976, p ¼ 0.02).
Conclusions: Given the high prevalence of sexual dysfunction in MS patients and the significant impact
it has on HRQoL, more research on this often overlooked symptom of MS could be very informative for
patients that are deciding to initiate a new disease modifying therapy.
Keywords: Sexual dysfunction, natalizumab, quality of life, patient-reported outcomes
Date received: 20 March 2018; Revised received 24 April 2018; accepted: 16 May 2018

Introduction
Multiple sclerosis (MS) is a chronic, immunemediated disease of the central nervous system
(CNS) that affects approximately 2–2.5 million
people worldwide.1 Approximately 85% of patients
present with a relapsing-remitting course, with a
majority later developing a secondary progressive
course characterized by slow accumulation of disability. This leads to a heterogenic patient population with symptoms involving disturbances of many
different systems of the human body including

visual, motor, sensory, coordination, balance,
bowel, bladder, sexual, and cognitive.
Sexual dysfunction is a common symptom experienced by patients with MS; the estimated prevalence
ranges between 40 and 80%.2 Sexual dysfunction is
often divided into primary (damage directly from
MS lesions in areas involving sexual response leading to difficulties with arousal and reaching orgasm),
secondary (signs associated with sexual response
including motor weakness, muscle spasticity, fatigue
and pain related to inadequate lubrication) and
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tertiary (psychological and sociological impairment).3 Sexual dysfunction often can result in loss
of self-esteem and a noted decrease in health-related
quality of life (HRQoL). A recent study involving
MS patients demonstrated that sexual dysfunction
had a much larger detrimental impact on HRQoL
parameters than did severity of physical disability,
highlighting its key role in patients’ perceptions of
well-being and the importance of incorporating it
into clinical evaluations.2
Natalizumab (TysabriVR , Biogen, Cambridge, MA) is
a disease-modifying therapy approved for the treatment of relapsing forms of MS.4 Beyond its effect on
traditional MS clinical measures, it has been demonstrated that patients receiving natalizumab have
improved HRQoL parameters, particularly fatigue
and cognition.5,6 These positive treatment effects,
in addition to our own anecdotal clinical experience
utilizing natalizumab, have led us to hypothesize
that there may be key improvements as a result
of natalizumab administration with respect to
sexual dysfunction, leading to an improvement in
HRQoL. Here we report findings on patients’ perceived sexual dysfunction changes over 24 weeks
after starting treatment with natalizumab.
Study design and patients
This was a single-center, nonrandomized, openlabel, single-arm, 24-week study conducted at our
MS Center in Tampa, FL, USA. From 2011 to
2012, 45 patients were screened aged 18 to 65
years with relapsing forms of MS who were naı̈ve
to natalizumab and had a suboptimal response to, or
tolerability issues with, other MS disease-modifying
therapies. Inclusion criteria required patients to: (a)
have stable disease as defined by not experiencing a
MS relapse within previous 30 days before baseline,
and (b) enroll in the Tysabri Outreach: Unified
Commitment to Health (TOUCHVR ) Prescribing
Program. Additional enrollment criteria included a
required baseline level of 15 for the primary scale on
the MS intimacy and sexuality questionnaire-19
(MSISQ-19) to demonstrate a clear level of sexual
dysfunction due primarily to MS. In the original
design we excluded patients with a moderate to
high level of symptoms suggestive of depression as
demonstrated by a score of  21 on the Beck depression inventory II (BDI-II). Due to the large number
of screen failures due solely to this criterion, we
removed it and analyzed the differences between
baseline scores and post-treatment scores. Patients
with major depressive disorder were excluded from
the study. Other exclusion criteria included primary
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progressive or secondary progressive MS without
relapses; treatment with medications known to aid
in erectile dysfunction, such as phosphodiesterase-5
inhibitors, within 30 days of study initiation;
and past medical history of diabetes mellitus.
Patients who felt they would be unable to complete
the study questionnaires were also excluded. The
study was approved by the University of South
Florida Institutional Review Board and conducted
in accordance with the Declaration of Helsinki
and International Conference on Harmonisation
Guideline on Good Clinical Practice. All patients
provided written informed consent.
Methods
Enrolled patients received natalizumab (300 mg
intravenously every 28 days) and completed evaluations of sexual dysfunction, QoL, depression, social
and emotional well-being, mobility and fatigue at
four visits at least 14 days apart, which included
the screening/baseline visit (naı̈ve to natalizumab
therapy) and weeks 4, 12, and 24 after initiation of
natalizumab therapy. The primary endpoint was
change in the primary subscale of the MSISQ-19
score from baseline to week 24. The MSISQ-19 is
a self-report patient-reported outcome (PRO) instrument for assessing the influence of MS symptoms
on sexual activity and satisfaction. This patient
questionnaire consists of 19 items divided into
three subscales. There are five levels of responses
(never, almost never, occasionally, almost always,
and always) to each item based on its interference
with sexual activity. The MSISQ-19 has demonstrated reliability and criterion validity in MS patients.7,8
The MSISQ-19 primary subscale demonstrates
a direct physical effect that MS has on the physical
component of sexual dysfunction. The secondary
subscale of the MSISQ-19 cover questions about
the patients’ other symptoms secondary to MS
(such as spasticity, tremors, and concentration).
The tertiary subscale then opens up the psychological aspects of sexual dysfunction. Secondary endpoints of the study included the change in the
sexual function subscale of the multiple sclerosis
quality of life-54 (MSQOL-54) questionnaire, the
change in the overall quality of life subscale of the
MSQOL-54, the change in score on the functional
assessment of multiple sclerosis (FAMS) questionnaire, and the change in score on the BDI-II questionnaire over 24 weeks after treatment initiation.
Two measures of HRQoL include the EuroQoL-5D
questionnaire and the short form-36 patient questionnaire. Decreased health utility, and poor scores in
other such domains on these questionnaires, have
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been shown to correlate with higher expanded disability status scale (EDSS) scores.9–12 EDSS is a
means of grading disability in MS and tracking its
progression over time. Although sexual dysfunction
is not explicitly captured by the EDSS, a reduction
in sustained disability progression as measured by
the EDSS is seen with natalizumab as compared
with placebo.4 The MSQOL-54 is a valid PRO
self-report questionnaire that contains 52 items, distributed into 12 subscales, and two single items.
The subscales are: physical function, role limitations
physically and emotionally, pain, emotional wellbeing, energy, health perceptions, social function,
cognitive function, health distress, overall QoL,
and sexual function. The single-item measures are
satisfaction with sexual function and change in
health. The MSQOL-54 mental composite score
includes five subscales measuring health distress,
overall quality of life, emotional well-being, role
limitations (emotional) and cognitive function. The
MSQOL-54 sexual function subscale includes four
gender specific questions that covered the physical
aspects of sexual function. The FAMS questionnaire
includes six sub-classes (mobility, symptoms, emotional well-being/depression, general contentment,
thinking/fatigue, and family/social well-being) comprised of 59 items, 44 of which are used for scoring
purposes. Each question is responded to with a ranking level from 0 (not at all) to 4 (very much). Higher
scores on the FAMS indicate better QoL. The BDI-II
is a widely used patient self-report inventory for
depression. Patients choose one statement from
each of 21 groups. Statements are ranked by severity
level from 0 to 3; higher summative BDI-II scores
indicate higher severity of symptoms suggestive
of depression.
Analysis of data
Baseline demographic and disease characteristics
including age and gender were summarized using
descriptive
statistics.
Baseline
MSISQ-19,
MSQOL-54, FAMS, and BDI-II scores were collected at a standard clinic visit at which the decision was
made to initiate natalizumab for the treatment
of relapsing MS. Due to the variation in insurance
provider approval times, the data was collected anywhere from 14 days to more than 90 days prior to the
first natalizumab infusion. Analyses were performed
using the patient last follow-up visit in comparison
to baseline scores; these were completed without
imputation. Changes in sexual dysfunction measured
over time per subject were analyzed using linear
mixed modeling in SAS 9.4VR software that
accounted for non-independence of measures by

www.sagepub.com/msjetc

treating subject as a random factor to define residuals for this model. Of the patients enrolled, 7 of the
15 completed all four time points of data collection
(baseline, week 4, week 12 and week 24); the
remaining 8 patients completed their last time
point before week 24.
Analysis of covariance was used to assess associations between patient baseline characteristics and
changes from baseline in QoL, depression symptoms
and additional PRO scores at 24 weeks. To assess
relationships between sexual dysfunction data and
other characteristics of the patients (e.g., age,
depression scores), Spearman correlation coefficients were determined for baseline data and for all
post-baseline measurements. Analyses were performed using the intent-to-treat population; all
patients with at least one completed follow-up
assessment were included.
Results
Patient characteristics
Of the 45 patients who were screened, a total of
15 patients were enrolled and were treated with natalizumab (Figure 1). The last 10 patients (of the total
15) were enrolled after the exclusion criteria was
amended to allow inclusion of patients whose symptoms of depression scores were 21 on the BDI-II,
as described previously. Patients who screened
but did not continue were lost to follow-up (which
included those who did not initiate therapy). Table 1
shows patient demographics and multiple sclerosis
disease course information amongst study participants including past disease modifying therapy
(DMT) history and usage. Glatiramer acetate had
been the most widely used previous DMT prior to
switching to natalizumab, followed by Interferonbeta-1a; 26% of participants were naı̈ve to previous
MS disease modifying therapy. The ratio of women
to men was 3:1 as typically seen in the demographics
of this disease. Median MS disease duration amongst
all participants was 7 years.
Changes in sexual dysfunction and quality of life
measures during treatment with natalizumab
The primary subscale of the MSISQ-19 questionnaire showed a statistically significant decrease in
mean score of sexual dysfunction over time in
patients on natalizumab therapy (–0.6976,
p ¼ 0.02), as shown in Table 2. The secondary and
tertiary effects of MS on sexual function (such as
spasticity, bowel/bladder symptoms, pain, and feelings of dependence or inadequacy), as measured by

3

Multiple Sclerosis Journal—Experimental, Translational and Clinical

Figure 1. Participant recruitment and retention.

Table 1. Subject demographics and disease
characteristics of the study population (n ¼ 15).
Characteristic

Value

Age, mean (years)
Disease duration, median (range)
Number of relapses
in past year, mean  SD
Time (months) since most
recent relapse, median (range)
Used prior MS treatment, %
Gender
Male, n (%)
Female, n (%)
Prior MS treatment, %
Interferon-beta-1a
Interferon-beta 1-b
Glatiramer acetate
Fingolimod
None

41.13
7 (2–22)
0.65  0.573
3 (0–17)
73
4 (26.7%)
11 (73.3%)
20
7
40
7
26

mean scores on the secondary and tertiary subscales
of the MSISQ-19, did not meet statistical significance
(0.019, p ¼ 0.96; –0.048, p ¼ 0.86). Other HRQoL
scores analyzed for changes over time included the
FAMS score (2.57, p ¼ 0.01), the MSQOL-54 mental
composite score (1.59, p ¼ 0.08) and MSQOL-54
sexual function subscale (2.7, p ¼ 0.09). Table 2
shows change in subjective, patient-reported quality
of life metrics over the course of 6 months of natalizumab treatment including measurements of depression, functionality in daily life, sexual health, and
overall quality of life. Overall the greatest positive
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change that achieved statistical significance over
the course of the 6 months was seen on the FAMS,
while the only negative change observed that
achieved statistical significance during this time
period was on the MSISQ, which are both
positive clinical change indicators.
Correlations between sexual dysfunction, age, and
baseline depression symptom scores
Spearman correlation coefficients were not statistically significant for relationships between age and
depression symptoms, age and primary sexual dysfunction, depression symptoms and primary sexual
dysfunction, or gender and depression symptoms.
These were also stratified by gender with no statistically significant differences noted. Due to one male
patient being lost to follow up, only three were
included in this analysis.
Discussion
Sexual dysfunction in MS has unfortunately received
relatively scant research evaluating its impact on
HRQoL parameters, despite its high prevalence in
MS patients.5 HRQoL metrics, in clinical studies
and, to a lesser extent, in clinical practice, are
being utilized more frequently to evaluate the
impact of MS from the patient’s perspective, in addition to evaluation of treatment effects on HRQoL. It
has been well demonstrated that natalizumab has
many clinical benefits for patients with relapsing
MS, including reduction in clinical relapses, slowing
of the accumulation of disability, decrease in MRI
lesion burden, improvement in fatigue, and improvement or stability of cognitive performance.4,6,13 To
our knowledge, this was the first study to address
sexual dysfunction changes in patients that are
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Table 2. Changes in quality of life scale scores from baseline to month 6.
Quality of life measure

Baseline
mean

Change over
6 months

p Value

BDI, meanSD
FAMS, mean  SD
MSISQa, mean  SD
MSISQb, mean  SD
MSISQc, mean  SD
MSQOL, mean  SD
MSQOLd, mean  SD
MSQOLe, mean  SD
MSQOLf, mean  SD

18.7  11.9
86.7  36.2
17.5  2.9
23.7  6.0
12.5  4.7
55.2  18.3
48.3  21.5
43.1  24.5
38.8  26.1

–0.6  0.48
2.57  0.99
–0.697  0.29
0.019  0.39
–0.048  0.28
0.73  0.71
1.59  0.88
0.29  0.67
16.1  34.1

0.22
0.01
0.02
0.96
0.87
0.31
0.08
0.66
0.46

Follow-up for all patients did not occur at 6 months and may be calculated using last visit
(1–6 month follow-up) in repeated measures model. BDI: Beck’s depression index; FAMS:
functional assessment of multiple sclerosis; MSISQ: multiple sclerosis intimacy and sexuality questionnaire; MSQOL: multiple sclerosis quality of life.
a
Primary sub-scale (items 12,16,17,18,19).
b
Secondary sub-scale (items 1,2,3,4,5,6,8,10,11).
c
Tertiary sub-scale (items 7,9,13,14,15).
d
QOL as related to mental health.
e
QOL as related to physical health.
f
QOL as related to sexual function.

initiating natalizumab therapy. In our study we
found that patients with known sexual dysfunction
experienced a decrease in these symptoms while
on natalizumab therapy, as demonstrated by a reduction on the primary subscale of the MSISQ-19.
For example, the nearly 1-point improvement can
translate from a sexual dysfunction symptom occurrence of “occasionally” reduced to “almost never”
or another example from “almost always” to
“occasionally” which has a very real potential to
positively impact QoL. However, the small sample
size was a limiting factor on the interpretation of our
results. Therefore, an increase in sample size could
have allowed for a more clinically meaningful
improvement to be realized. They also experienced
improved QoL overall while on natalizumab, as
demonstrated by increased scores on the FAMS, a
validated PRO tool for assessing HRQoL in MS.
Surprisingly, the secondary and tertiary subscale of
the MSISQ-19 did not show significant change with
natalizumab treatment. Although sexual dysfunction
clearly can have a significant impact on HRQoL, the
underlying etiology remains unclear. A prior study
demonstrated an association between sexual dysfunction and sphincteric dysfunction in patients
with MS, indicating that the same segments of the
autonomic innervation controlling sphincteric function may be implicated in sexual dysfunction in
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these patients.14 Additionally, MS-related sexual
dysfunction could be due to psychological factors
such as depression and anxiety, fatigue, muscle
weakness, muscle spasms, dysesthesias and pain,
and side effects of commonly prescribed symptomatic medications including anticonvulsants, antidepressants, and bladder medications.15 There is an
established high prevalence of sexual dysfunction
in those with severe depression.16 Given this potential confounding variable, we excluded patients with
a moderate to high level of depression symptoms as
demonstrated by a score of  21 on the BDI-II. This
criterion led to a high number of screen failures for
patients attempting to enroll in the study therefore a
protocol amendment was implemented to remove
this exclusion criterion. We analyzed the differences
between baseline scores and post-treatment scores.
The results were not statistically significant for relationships between depression symptoms scores and
primary sexual dysfunction.
Our study had several limitations that prevent any
definitive conclusions about the effects of natalizumab on sexual dysfunction. First, we had a relatively
small sample size. Second, due to variability in
scheduling of the natalizumab infusions, complete
data capture for all study patients was difficult.
Approximately 50% of patients completed all protocol specified follow-up and nearly 75% of patients
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had complete data through week 12. Third, the lack
of a placebo group or active comparator arm in the
study design also contributed to the interpretation of
the results. These limitations would be a potential
explanation as to why the primary subscale of
MSISQ-19 did show a statistically significant reduction with initiation of natalizumab therapy while the
secondary and tertiary subscale of the MSISQ-19
did not.
Conclusion
Our study results strengthen the growing evidence
that PROs have an important role in measuring the
effects of various treatments for MS, including natalizumab. Standard outcome measures that have routinely been utilized in making treatment decisions
for MS patients include neurologic disability, relapse
history, and MRI lesion burden. HRQoL metrics,
such as PROs, record the impact of the disease
from the patient’s perspective and should be considered by healthcare providers in conjunction with these
standard outcome measures. Given its high prevalence in MS and its significant impact on patientreported HRQoL, sexual dysfunction could benefit
from further research; specifically, more studies are
needed to assess the relative effects of current MS
treatments on sexual dysfunction and QoL.
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